By contrast, many studies have shown that newer antihypertensive agents, such as CCBs, ARBs and ACE inhibitors, provide additional benefits by reducing the incidence of CV events in patients with hypertension (14,16,25,30). This evidence concerns the gene ACE and hypertensive disorder.